News & Events
Vedanta Biosciences CEO Receives 2019 Immigrant Entrepreneur Award (opens in a new tab)
CAMBRIDGE, Mass.–(BUSINESS WIRE)– Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on defined bacterial consortia, is pleased to announce that its co-founder and CEO Bernat Olle, Ph.D., received the 2019 Barry M. Portnoy Immigrant Entrepreneur Award…
Interview with Jim Weston and Stephen Conafay of MTIG (opens in a new tab)
Microbiome Therapeutics Innovation Group Highlights Member Company Activity at IDWeek 2019 (opens in a new tab)
Vedanta Biosciences Announces $16.6 Million Series C-2 Financing (opens in a new tab)
New funding brings total Series C and C-2 capital raised to $62.1 million CAMBRIDGE, Mass.–(BUSINESS WIRE)– Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria, today announced a $16.…
Rebiotix, Inc. and Karolinska Institutet Expand Partnership to Shape the Future of Microbiome Research (opens in a new tab)
The post Rebiotix, Inc. and Karolinska Institutet Expand Partnership to Shape the Future of Microbiome Research appeared first on Rebiotix.…
LUCA Biologics Launches to Develop Live Biotherapeutics for Women’s Health Starting with Urinary Tract Infection (UTI) (opens in a new tab)
Seres Therapeutics Appoints Stephen Berenson to its Board of Directors (opens in a new tab)
Seres Therapeutics Reports Second Quarter Financial Results and Provides Progress Update (opens in a new tab)
Seres Therapeutics to Present at the Canaccord Genuity 39th Annual Growth Conference (opens in a new tab)
Seres Therapeutics to Host Second Quarter 2019 Financial Results and Operational Progress Conference Call and Webcast on August 6, 2019 (opens in a new tab)
Improvement of Microbiome Health Index in Patients with Recurrent Clostridioides difficile Infections Following RBX2660 Treatment is Associated with a Reduction in Antimicrobial Resistance Genes (opens in a new tab)
The post Improvement of Microbiome Health Index in Patients with Recurrent Clostridioides difficile Infections Following RBX2660 Treatment is Associated with a Reduction in Antimicrobial Resistance Genes appeared first on Rebiotix.…
Seed Health Joins Microbiome Therapeutics Innovation Group (opens in a new tab)
Rebiotix Leaders to Discuss Microbiome Product Development Challenges and Regulation at Microbiome Movement – Drug Development Summit 2019 (opens in a new tab)
Vedanta Biosciences Announces First Patient Enrolled in VE416 Phase 1b/2 Food Allergy Clinical Study (opens in a new tab)
Vedanta Biosciences’ Silvia Caballero, Ph.D., Named as an MIT Technology Review Global Innovator Under 35 (opens in a new tab)
Response to Microbiota-Based Drug RBX2660 is Associated with Reduction in Antimicrobial Resistance Genes in Patients with Recurrent Clostridioides difficile Infections (opens in a new tab)
Julia Garcia-Diaz MD, Courtney Jones, Hiren Karathia PhD, Brian Fanelli, Nur A Hasan PhD, Ken Blount PhD Background Antibiotic microbial resistance (AMR) is a global health challenge, and is common in recurrent Clostridioides difficile infection (rCDI) population due to high historical exposure to antibiotics. The gut …
Seres Therapeutics Issues Statement Regarding U.S. Food and Drug Administration Safety Alert Related to Use of Fecal Microbiota Transplantation (opens in a new tab)
Microbiome Therapeutics Innovation Group Statement on FDA Safety Alert Regarding Use of Fecal Microbiota for Transplantation and Risk of Serious Adverse Reactions Due to Transmission of Multi-Drug Resistant Organisms (opens in a new tab)
Seres Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock (opens in a new tab)
Seres Therapeutics, Inc. Announces Proposed Public Offering of Common Stock (opens in a new tab)